Radio fusion

How Fusions’ Ac-225 linker improves radiopharmaceutical safety for cancer

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225.

While the newco remains tight-lipped about the linker’s design, SVP of Business Development and U.S. Operations Marc Schwabish told BioCentury the company has shown its linkers improve the safety of IV antibody-radioisotope conjugates over those based

Read the full 580 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE